Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one‐year randomized controlled trial comparing systematic versus on‐demand treatment

Bréban, Maxime; Ravaud, Philippe; Claudepierre, Pascal; Baron, Gabriel; Henry, Yves-Dominique; Hudry, Christophe; Euller‐Ziegler, Liana; Pham, Thao; Solau-Gervais, Élisabeth; Chary‐Valckenaere, Isabelle; Marcelli, Christian; Perdriger, Aleth; Loët, Xavier Le; Wendling, Daniel; Fautrel, Bruno; Fournie, B.; Combe, Bernard; Gaudin, Philippe; Jousse, Sandrine; Mariette, Xavier; Baleydier, A.; Trape, Gérard; Dougados, Maxime

doi:10.1002/art.23167

Cited by 119 publications

(95 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical data indicate that the uninterrupted use of TNF-α blockers is more effective than their use "on demand," supporting the use of higher cumulative doses [34]. Further studies are needed to better characterize the long-term safety profi le of TNF blockers.…”

Section: Safetymentioning

confidence: 95%

The treatment of psoriatic arthritis and inflammatory spondylitis

Castro-Rueda

Kavanaugh

2008

Current Science Inc

View full text Add to dashboard Cite

NSAIDs still remain the initial therapeutic modality for psoriatic arthritis and inflammatory spondylitis. Disease-modifying antirheumatic drugs have only been proven to be useful in peripheral arthritis, without efficacy in axial inflammatory spondylitis. In recent years, the introduction of tumor necrosis alpha inhibitors into clinical practice has produced a substantial impact in both peripheral and axial disease, with improvement in pain, function, and quality of life. Factors such as cost-effectiveness and safety will need to be better characterized over time.

show abstract

Section: Safetymentioning

confidence: 95%

The treatment of psoriatic arthritis and inflammatory spondylitis

Castro-Rueda

Kavanaugh

2008

Current Science Inc

View full text Add to dashboard Cite

show abstract

“…In a French study, it was formally proven that the strategy to administer infliximab continuously rather than on demand leads to superior efficacy [23]. Furthermore, the addition of methotrexate did not improve the efficacy or safety of infliximab in that study; this is in contrast to the experience in patients with RA [23,24].…”

Section: Anti-tumor Necrosis Factor-α Agentsmentioning

confidence: 96%

Update on Biologic Therapy in the Management of Axial Spondyloarthritis

et al. 2010

View full text Add to dashboard Cite

Axial spondyloarthritis, which includes ankylosing spondylitis and psoriatic spondyloarthritis, is an important subtype of the spondyloarthritides. Tumor necrosis factor (TNF) antagonists are effective therapies for this partially heterogeneous group of rheumatic diseases in terms of signs, symptoms, and functioning, but they do not seem to substantially inhibit radiographic progression, which is mainly new bone formation in ankylosing spondylitis. However, they clearly reduce inflammation, as shown by MRI. TNF blockers are also efficacious in the treatment of extraspinal features of spondyloarthritis. In addition, evidence indicates that anti-TNF therapy works well in early axial disease. Other biologics are currently being investigated, as alternatives are needed for patients who fail anti-TNF therapy.

show abstract

“…At the moment, studies of the fifth available TNFα blocker certolizumab are being performed. The additional use of methotrexate (MTX), as known from RA, did not show any additional benefit [28].…”

Section: Biologic Agents Targeting Tnfαmentioning

confidence: 98%

Biologic Therapies for Spondyloarthritis: What Is New?

Baraliakos

Braun

2012

Curr Rheumatol Rep

View full text Add to dashboard Cite

The course of axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS), is strongly influenced by the degree of disease activity over time, which is mainly based on inflammation, and by the impairment of function, which is based on structural damage-mainly, new bone formation-and inflammation. In AS, nonsteroidal anti-inflammatory agents are currently recommended as the first choice of medical therapy, and there is also a clear role for regular exercise and physiotherapy in order to preserve and prevent loss of spinal mobility. For patients who have insufficiently responded to conventional medications, there are now four biologics approved for the treatment of patients with active AS in many countries, all directed against TNFα: infliximab, etanercept, adalimumab, and golimumab; studies with certolizumab are currently ongoing. Several studies with patients classified as nonradiographic axSpA have also shown a good response to TNF blockers; in patients with early disease and high CRP levels, the response rates were even better. Long-term studies with TNF blockers have shown declining retention rates over time but sustained clinical efficacy in the patients who remained on treatment. States of drug-free remission are rarely reached and only for relatively short periods of time. More studies including magnetic resonance imaging (MRI) are needed to further examine the lack of effect of anti-TNF treatment on radiographic progression in the axial skeleton. Whether the effect of an early intervention with biologics will prevent the development of bone growth in patients with nonradiographic axial SpA remains to be seen. Biologics other than TNF blockers are currently not recommended for the treatment of patients with axSpA, because of insufficient evidence of clinically relevant efficacy. The anti-IL-17a antibody secukinumab may be efficacious, on the basis of a proof-of-concept trial. Finally, first data on biosimilars of TNF blockers have recently been presented.

show abstract

Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one‐year randomized controlled trial comparing systematic versus on‐demand treatment

Cited by 119 publications

References 37 publications

The treatment of psoriatic arthritis and inflammatory spondylitis

The treatment of psoriatic arthritis and inflammatory spondylitis

Update on Biologic Therapy in the Management of Axial Spondyloarthritis

Biologic Therapies for Spondyloarthritis: What Is New?

Contact Info

Product

Resources

About